203 related articles for article (PubMed ID: 38356845)
21. Prognostic value of the modified Glasgow prognostic score in biliary tract cancer patients: a systematic review and meta-analysis.
Zhou Y; Liu Z; Cheng Y; Li J; Fu W
J Gastrointest Surg; 2024 Apr; 28(4):559-565. PubMed ID: 38583910
[TBL] [Abstract][Full Text] [Related]
22. Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Luan CW; Kuo LT; Wang YT; Liao CT; Kang CJ; Lee YC; Chen KY; Lai CH; Tsai YH; Huang EI; Tsai MS; Hsu CM; Chang GH; Tsai YT
Head Neck; 2023 Jul; 45(7):1856-1867. PubMed ID: 37161915
[TBL] [Abstract][Full Text] [Related]
23. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
24. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.
Hanai N; Sawabe M; Kimura T; Suzuki H; Ozawa T; Hirakawa H; Fukuda Y; Hasegawa Y
Oncotarget; 2018 Dec; 9(97):37008-37016. PubMed ID: 30651931
[TBL] [Abstract][Full Text] [Related]
25. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.
Chen Z; Nonaka H; Onishi H; Nakatani E; Sato Y; Funayama S; Watanabe H; Komiyama T; Kuriyama K; Marino K; Aoki S; Araya M; Tominaga L; Saito R; Maehata Y; Oguri M; Saito M
J Radiat Res; 2021 May; 62(3):457-464. PubMed ID: 33866376
[TBL] [Abstract][Full Text] [Related]
26. Modified Glasgow prognostic score might be a prognostic factor for hepatocellular carcinoma: a meta-analysis.
Chen H; Hu N; Chang P; Kang T; Han S; Lu Y; Li M
Panminerva Med; 2017 Dec; 59(4):302-307. PubMed ID: 28001023
[TBL] [Abstract][Full Text] [Related]
27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
28. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
29. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score.
Hirahara N; Matsubara T; Kaji S; Kawabata Y; Hyakudomi R; Yamamoto T; Uchida Y; Ishitobi K; Takai K; Tajima Y
Oncotarget; 2020 Nov; 11(45):4169-4177. PubMed ID: 33227100
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study.
Kasahara K; Enomoto M; Udo R; Tago T; Mazaki J; Ishizaki T; Yamada T; Nagakawa Y; Katsumata K; Tsuchida A
BMC Cancer; 2022 Jan; 22(1):20. PubMed ID: 34980009
[TBL] [Abstract][Full Text] [Related]
31. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
Front Oncol; 2022; 12():962173. PubMed ID: 36059629
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies.
Jin J; Hu K; Zhou Y; Li W
Int J Biol Markers; 2018 May; 33(2):201-207. PubMed ID: 29076522
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
Asama H; Suzuki R; Takagi T; Sugimoto M; Konno N; Watanabe K; Nakamura J; Kikuchi H; Takasumi M; Sato Y; Irie H; Hikichi T; Ohira H
Mol Clin Oncol; 2018 Oct; 9(4):408-414. PubMed ID: 30233794
[TBL] [Abstract][Full Text] [Related]
35. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-200 families and prognostic value in various carcinomas: A systematic review and meta-analysis.
Yin Y; Song WW; Wang Y; Zhao W; Wu J; Xu W
Aging Med (Milton); 2018 Jun; 1(1):39-45. PubMed ID: 31942478
[TBL] [Abstract][Full Text] [Related]
37. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
[TBL] [Abstract][Full Text] [Related]
38. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
39. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients.
Yu Y; Qian L; Cui J
Mol Clin Oncol; 2017 Sep; 7(3):498-506. PubMed ID: 28811903
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.
Minami S; Ihara S; Kim SH; Yamamoto S; Komuta K
World J Oncol; 2018 Feb; 9(1):13-20. PubMed ID: 29581811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
